DUBLIN–(BUSINESS THREAD)–The “Digital Marketing Trends in Severe Asthma” the report has been added ResearchAndMarkets.com’s offers
Sanofi/Regeneron’s Dupixent.com had the highest traffic on branded severe asthma patient sites in the US from July 2021 to June 2022, with about 7,800,000 visits, followed by Novartis’ Xolair.com and Nucala.com by GSK.
The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca’s Tezspire.com had the highest amount of direct traffic (83%), while the other brands, Dupixent, Cinqair, Nucala and Xolair, had levels between 52 and 66%.
For patient-branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at about $4.2 million, followed by GSK’s Nucala.com at roughly $900,000. Dupixent.com was supported by the highest paid keywords with approximately 10,650 keywords, followed by Tezspire.com with approximately 5,800 keywords.
For branded HCP sites in the US, Sanofi/Regeneron’s Dupixenthcp.com had the highest number of visits with approximately 775,000 total visits, followed by AstraZeneca’s Fasenrahcp.com and GSK’s Nucalahcp.com. The highest proportion of traffic to these sites originated from direct sources, followed by organic and referral sources.
Teva’s Cinqairhcp.com had the highest proportion of direct search traffic (81%). Sanofi/Regeneron spent the most on DDA for Dupixenthcp.com at about $51,400, followed by Amgen/AstraZeneca’s Tezspirehcp.com at about $17,100.
Between July 2021 and June 2022, the top 20 asthma social media posts by pharmacy interaction were from the Sanofi Facebook, Genentech Instagram, Regeneron Instagram, Fasenra Facebook, and GSK Instagram accounts. AstraZeneca’s Vik Asthma is the only drugstore-detected severe asthma app in the US, with an estimated 30,700 downloads in 2021.
The majority of branded websites in EUCAN are patient-facing and few generated significant traffic between July 2021 and June 2022. Sanofi/Regeneron’s Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with around 20,200 and 3,400 visits, respectively.
Between July 2021 and June 2022, eight of the top 20 asthma social media posts by EUCAN pharmacy interaction were from AstraZeneca Espana’s Instagram account. No pharmacy asthma mobile apps detected in EUCAN.
scope
This report evaluates key digital marketing metrics for pharmaceutical assets in severe asthma, including branded patient and healthcare professional (HCP) websites, mobile apps and social media accounts. Metrics include website traffic volume, engagement and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads and post engagement in social networks. Countries include the US, 4EU (Italy, France, Germany and Spain), UK and Canada (EUCAN).
Reasons to buy
Understand the competitive landscape of digital marketing in severe asthma, with an insight into key patient and healthcare professional brand assets across regions. See what tactics pharmaceutical companies are using to drive traffic to their severe asthma brand assets for patients and healthcare professionals, including DDA and paid SEO. Understand which website traffic sources drive the most visits to these assets, such as paid SEO, social media, or organic search. Compare the most important brand assets for patients based on how they address and support different patient needs. See which severe asthma pharma social media accounts are the most active and get the most engagement. Check out the top severe asthma mobile app deals from pharmacies in different regions.
Key topics covered:
Executive Summary US Patient Branded Websites US HCP Branded Websites US Digital Display Advertising & Search Engine Optimization US Mobile Apps & Social Media EUCAN Branded Websites EUCAN Mobile Apps & Social Media appendix
Companies mentioned
Sanofi Regeneron Genentech Novartis GSK AstraZeneca Amgen Teva
For more information on this report, visit
[ad_2]
Source link
